Rituximab biosimilar (JHL Biotech)

利妥昔单抗生物类似药 (JHL Biotech)

Report date: 2024/01/02 20:03:52

Base Information

Drug NameRituximab biosimilar (JHL Biotech)
Drug Alias Name利妥昔单抗生物仿制药 (JHL Biotech)JHL-1101
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmArthritis, RheumatoidLymphoma, T-Cell +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBosnia and HerzegovinaBulgaria +[13] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesEden Biologics Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesJhl Biotech Usa IncRutgers UniversityXikang (Wuhan) Biomedicine Co Ltd
Active IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmLymphoma, FollicularLymphoma, Large B-Cell, Diffuse
Inactive IndicationsArthritis, RheumatoidLymphoma, T-CellLymphoma, B-Cell +[5] 

Other Information

ATC CodeL01XC02
Related LinksN/A